Trending

Lynparza

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as

X

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

https://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

GlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the

X

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

https://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this

X

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

https://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/

AZ/MSD’s Lynparza sees positive results in prostate cancer

AZ/MSD’s Lynparza sees positive results in prostate cancer

AstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant

X

AZ/MSD’s Lynparza sees positive results in prostate cancer

https://pharmaphorum.com/news/az-msds-lynparza-sees-positive-results-in-prostate-cancer/

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer

GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid

X

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer

https://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/

Lynparza on cusp of approval for advanced ovarian cancer

Lynparza on cusp of approval for advanced ovarian cancer

Breast cancer drug Lynparza (olaparib) is poised for EU approval for the first-line treatment of a certain type

X

Lynparza on cusp of approval for advanced ovarian cancer

https://pharmaphorum.com/news/lynparza-on-cusp-of-approval-for-advanced-ovarian-cancer/

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced

X

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

https://pharmaphorum.com/news/az-and-msds-lynparza-gets-eu-nod-for-hard-to-treat-breast-cancer/

AstraZeneca cancer drugs approved in Japan

AstraZeneca cancer drugs approved in Japan

AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months

X

AstraZeneca cancer drugs approved in Japan

https://pharmaphorum.com/r-d/astrazenecas-cancer-drugs-approved-japan/

Tesaro and Roche to combine drugs in bladder cancer trials

Tesaro and Roche to combine drugs in bladder cancer trials

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.

X

Tesaro and Roche to combine drugs in bladder cancer trials

https://pharmaphorum.com/news/tesaro-roche-combine-drugs-bladder-cancer-trials/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com